rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

John Craig Thompson

Director

Company insider

Files Form 4 as: Director, Esperion Therapeutics; President & CEO, Anthera Pharmaceuticals; Chief Operating Officer, Tetraphase Pharmaceuticals; Chief Commercial Officer, Trius Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
46
Buys
3
Sells
6
Bought
$27K
Sold
$4.0M
Companies
4
Companies where not an officer
1
First trade
10 Jan 2011
Last trade
13 Jul 2026
Last filed
13 Jul 2026

Companies traded

Where they are an officer
Anthera PharmaceuticalsDirector, Officer · last 5 Jan 20182 buys · 0 sells
Tetraphase PharmaceuticalsOfficer · last 8 Sep 20150 buys · 6 sells
Trius TherapeuticsOfficer · last 11 Sep 20131 buy · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
Esperion TherapeuticsDirector · Biotechnology · last 13 Jul 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
13 Jul 2026filed 13 Jul 2026Esperion TherapeuticsBiotechnologySEC FORM 4 Code D—79,873filing
13 Jul 2026filed 13 Jul 2026Esperion Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—40,000filing
13 Jul 2026filed 13 Jul 2026Esperion Therapeuticsoption or derivativeSEC FORM 4 Code D—40,000filing
13 Jul 2026filed 13 Jul 2026Esperion TherapeuticsSEC FORM 4 Code D—79,873filing
28 May 2026filed 1 Jun 2026Esperion TherapeuticsBiotechnologySEC FORM 4 Code A—79,873 at $0.00filing
28 May 2026filed 1 Jun 2026Esperion TherapeuticsSEC FORM 4 Code A—79,873 at $0.00filing
1 Jul 2025filed 2 Jul 2025Esperion Therapeuticsoption or derivativeSEC FORM 4 Code A—40,000 at $0.00filing
5 Jan 2018filed 9 Jan 2018Anthera Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—1,847,074 at $0.00filing
20 Sep 2017filed 20 Sep 2017Anthera PharmaceuticalsSEC FORM 4 Bought$11K8,550 at $1.32filing
7 Sep 2017filed 7 Sep 2017Anthera PharmaceuticalsSEC FORM 4 Code M$15K10,400 at $1.43filing
7 Sep 2017filed 7 Sep 2017Anthera PharmaceuticalsSEC FORM 4 Bought$15K10,400 at $1.43filing
20 May 2017filed 22 May 2017Anthera Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—81,250 at $0.00filing
3 Mar 2017filed 3 Mar 2017Anthera Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—100,000 at $0.00filing
11 Jan 2017filed 6 Feb 2017Anthera PharmaceuticalsSEC FORM 4 Code A$3,9557,190 at $0.55filing
6 Dec 2016filed 3 Mar 2017Anthera Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—200,000 at $0.00filing
6 Dec 2016filed 6 Dec 2016Anthera Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—300,000 at $0.00filing
9 Jun 2016filed 13 Jun 2016Anthera Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—170,000 at $0.00filing
8 Sep 2015filed 10 Sep 2015Tetraphase PharmaceuticalsSEC FORM 4 Code M$145K10,000 at $14.45filing
8 Sep 2015filed 10 Sep 2015Tetraphase PharmaceuticalsSEC FORM 4 Sold$441K10,000 at $44.08filing
8 Sep 2015filed 10 Sep 2015Tetraphase Pharmaceuticalsoption or derivativeSEC FORM 4 Code M—10,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed9

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.